On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a ...

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...